News | Proton Therapy | November 01, 2017

PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy

Data presented in Chicago find that proton therapy lowers post-treatment costs, but pediatric patients face delay in coverage issues

PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy

November 1, 2017 – Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy at the Particle Therapy Cooperative Group – North America (PTCOG‐NA) meeting. During the meeting, two important abstracts were presented that addressed concerns about higher costs for proton therapy and delays in payer coverage for pediatric patients.

Leading physicians at the M.D. Anderson Cancer Center in Houston presented a recent study that demonstrated post‐treatment costs for esophageal cancer patients treated with proton therapy was lower than for patients who received intensity modulated radiation therapy (IMRT). The study results reflected that the higher post‐treatment costs for IMRT were due to additional procedures, treatments and/or hospitalization due to complications from their treatment.

Scott Warwick, executive director of the National Association for Proton Therapy, stated “This study presented today continues to confirm what we have known all along – treatment with proton therapy reduces patient complications resulting in reduced post‐treatment costs when compared to other radiation therapy modalities.”

An additional abstract addressing proton therapy coverage by payers for pediatric patients was presented by physicians from Massachusetts General Hospital and other proton centers. Data from the Pediatric Proton Consortium Registry, which collects information for children with cancer who are treated with proton therapy, was used for the study. That data reflected that while the majority of pediatric patients’ proton therapy treatment was covered by their payer, 6 percent of children experienced a delay in treatment while waiting for approval from the payer. These delays were more common in children covered by Medicaid (12 percent) than for children covered by a commercial insurer (5 percent).

Eugen Hug, M.D., president of PTCOG‐NA, commented that, “Several original scientific studies reported first in the conference confirm the increasing role of proton therapy in frequent cancers like breast cancer, prostate and esophageal cancer and its ability to increase cure rates and reduced side effects. Reduced costs from reduced side effects will offset some if not all of the higher initial costs of proton therapy. Unfortunately, even for the most vulnerable patients — children — access to proton therapy in timely fashion remains a challenge.”

Since PTCOG‐NA’s creation in 2013, the NAPT and PTCOG‐NA have worked collaboratively together to advance evidence‐based proton therapy coverage through cooperative research, development of a model coverage policy and advocacy.

For more information: www.ptcog-na.org

Related Content

New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...